Erin Alesi, MD
Hematology & Oncology · Richmond, VANPI 1679779540
Payments from drug & device makers
What this record shows
This record is dominated by education: $20 of the $24 with a category attached, or 82.4%. Merck accounts for 82.4% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology & oncology clinicians in VA, where the typical reported total is $1,232.
Across 2 payments — averaging $12.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$20
- Array Biopharma Inc$4
Across 64 payments — averaging $26,590 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1M
- Pfizer$251K
- AstraZeneca$102K
- AVEO Pharmaceuticals, Inc.$102K
- Seagen Inc.$90K
- Genentech, Inc.$44K
- plus $101K from 6 others
What the payments were for
- Food & beverage$418%
- Education$2082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $20 |
| Array Biopharma Inc | 1 | $4 |
How this compares
$24 in reported general payments places this provider in the 0th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 23 | $266,013 |
| EliquisApixaban | 27 | $22,880 |
| Ondansetron Hcl | 44 | $1,402 |
| Gabapentin | 15 | $627 |
| Prochlorperazine Maleate | 54 | $559 |
| Dexamethasone | 26 | $435 |
| Oxycodone Hcl | 32 | $337 |
| Duloxetine Hcl | 11 | $258 |
| Bicalutamide | 11 | $229 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 15 | $207 |
| Famotidine | 22 | $192 |
| Levothyroxine Sodium | 34 | $116 |
| Letrozole | 13 | $96 |
| Lidocaine Hcl ViscousLidocaine Hcl | 14 | $87 |
| Prednisone | 13 | $18 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Richmond
- Victor YazbeckRichmond$190K
- Attique SamdaniRichmond$104K
- Elke FriedmanRichmond$23K
- James KhatcheressianRichmond$23K
- Rachit KumarRichmond$12K
- Gisa SchunnRichmond$8K
- Asit PaulRichmond$7K
- Pablo GonzalezRichmond$6K
- Hashim MannRichmond$6K
- Joshua McFarlaneRichmond$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.